Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials
Maastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming […]